LMAT
Lemaitre Vascular IncPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| direct sales growth (organic) non-GAAP | 12.8% | Q1 2026 call | — |
| headcount | 641 | March 31, 2026 call | — |
| international autograph sales | $2.1M | Q1 2026 call | — |
| organic sales growth non-GAAP | 10% | Q1 2026 call | — |
| RSMs and country managers | 35 | Q1 2026 call | — |
| sales reps | 158 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LMAT
this stock
Lemaitre Vascular Inc
|
$2.33B | +25.8% | +13.5% | 37.4 | 5.6% |
|
ISRG
Intuitive Surgical Inc
|
$147.01B | -26.7% | +20.5% | 50.4 | 2.2% |
|
MDLN
Medline Inc.
|
$53.66B | -4.0% | +11.5% | — | 2.1% |
|
BDX
Becton Dickinson & Co
|
$41.49B | +0.0% | +8.2% | 57.2 | 2.6% |
|
ALC
Alcon Inc
|
$32.46B | -15.5% | — | — | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LMAT | +6.1% | +7.1% | +22.5% | +6.1% | +25.8% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +6.3% | +6.2% | +15.0% | +6.3% | +16.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.